Peptidomimetics Reactivate p53 by Blocking E6-p300 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies are inadequate for managing the growing number of HPV-positive head and neck squamous cell carcinoma (HNSCC) patients, as existing approaches do not effectively target the E6-p300 interaction, which is crucial for inactivating p53, a key factor in HPV-mediated tumorigenesis.
Innovation Solution
Development of peptidomimetics that mimic a helix structure to block the interaction between E6 and p300, thereby increasing p53 acetylation and activity, and potentially combining these with cis-platinum for enhanced anti-cancer effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic strategies are used, then treatment of HPV-positive HNSCC is attempted, but they fail to effectively target the E6-p300 interaction and reactivate p53
Solution Approach 1:
The patent uses peptidomimetics that copy the structure and function of the p300 CH1 domain helix to bind E6 and block its interaction with p300. The peptidomimetic compounds (Formulas I, II, III) are synthetic copies that replicate the key structural features (hydrogen bonding patterns, hydrophobic interactions) of the natural p300 helix, enabling them to compete with E6 for binding to p300 and restore p53 function.
2Reliability
If peptidomimetics are designed to mimic helix structure, then E6-p300 interaction is blocked and p53 is reactivated, but the molecular complexity of the compounds increases
Solution Approach 1:
The patent segments the p300 CH1 domain into its critical functional elements (hydrogen bonding residues, hydrophobic residues, turn regions) and recreates only these essential segments in the peptidomimetics. The compounds focus on mimicking the N-terminal portion of the CH1 domain that directly contacts E6, rather than replicating the entire domain, thus reducing complexity while maintaining function.
Solution Approach 2:
The patent changes the molecular parameters from natural amino acid sequences to synthetic peptidomimetic structures with modified backbones (Formulas I, II, III). The compounds use non-natural chemical structures that mimic the hydrogen bonding and hydrophobic interaction patterns of the natural helix, altering physical-chemical parameters while preserving biological function.
3Adaptability or versatility
If existing therapies are applied, then general cancer treatment is provided, but they do not specifically address HPV-mediated p53 inactivation through E6-p300 interaction
Solution Approach 1:
The patent introduces peptidomimetics as intermediary molecules that mediate between E6 and p300 by binding to E6 and preventing its interaction with p300. These synthetic compounds act as molecular mediators that disrupt the pathological E6-p300 complex formation, thereby restoring the normal p300-p53 interaction and p53 tumor suppressor function without directly modifying E6 or p300.
Data Source
AI summary
The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.